Please login to the form below

Not currently logged in
Email:
Password:

ReNeuron appoints new CEO

Olav Hellebø joins from Clavis Pharma
edit-Olav-Hellebo-CEO-1

UK-based stem cell therapy company ReNeuron Group has appointed Olav Hellebø as its new CEO with immediate effect.

Hellebø joins from Norwegian biotech Clavis Pharma where he held the same position and brings to the role over 20 years of experience in the pharma and biopharma industry.

During this time he built a multinational leadership team at Clavis, taking the company's lead programme through phase III clinical development and completing substantial fundraising and out-licensing transactions for the business.

Hellebø, who has also previously held directorship positions at Pharmalink and Palma Biotech, said ReNeuron impressed him with their technology, team and strong investment backing.

He added: “Regenerative medicine is very promising for advancing patient care in a multitude of diseases and I believe that the development of off-the-shelf stem cell therapies, such as ReNeuron's stem cell therapy candidates, will be the best way to ensure as many patients as possible have an opportunity to benefit from these advances in the future.”

Michael Hunt, who has held the position of CEO since July 2005, will remain on ReNeuron's Board as chief financial officer.

Bryan Morton, chairman of ReNeuron, commented: “I am delighted to welcome Olav Hellebø to the role of chief executive officer. His breadth of experience in healthcare and in the commercialisation of pharmaceuticals will be invaluable as ReNeuron moves to the next stage in the clinical and commercial development of its novel therapeutic candidates.”

8th September 2014

From: Research, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget....
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon....
Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...

Infographics